We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: May 8, 2003
Last Update Posted: August 5, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Repligen Corporation
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Condition Intervention Phase
Mitochondrial Diseases Drug: RG2133 (2',3',5'-tri-O-acetyluridine) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Treatment
Official Title: An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Resource links provided by NLM:

Further study details as provided by Repligen Corporation:

Estimated Enrollment: 12

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   3 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Mitochondrial Disease
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00060515     History of Changes
Other Study ID Numbers: RG2133-01
First Submitted: May 7, 2003
First Posted: May 8, 2003
Last Update Posted: August 5, 2005
Last Verified: August 2005

Additional relevant MeSH terms:
Mitochondrial Diseases
Metabolic Diseases